This information is mostly in reference to the now outdated entity of BAC, which included some invasive forms of disease. The treatment of choice in any patient with BAC is complete surgical resection, typically via lobectomy or pneumonectomy, with concurrent ipsilateral lymphadenectomy. Non-mucinous BAC are highly associated with classical EGFR mutations, and thus are often responsive to targeted chemotherapy with erlotinib and gefitinib. K-ras mutations are rare in nm-BAC. Mucinous BAC, in contrast, is much more highly associated with K-ras mutations and wild-type EGFR, and are thus usually insensitive to the EGFR tyrosine kinase inhibitors. In fact, there is some evidence that suggests that the administration of EGFR-pathway inhibitors to patients with K-ras mutated BAC may even be harmful.
Adenocarcinoma in situ of the lung
Epithelial-myoepithelial carcinoma of the lung
Salivary gland–like carcinoma of the lung
Minimally invasive adenocarcinoma of the lung
Sarcomatoid carcinoma of the lung
Mucinous cystadenocarcinoma of the lung
Adenocarcinoma of the lung
Pulmonary sclerosing pneumocytoma